Our Clinical Trials

Neuroblastoma

top

A Phase I Study of 3F8 Antibody plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma
Kushner, Brian, MD

[Protocol 05-015]
A Phase I Study of Intrathecal Radioimmunotherapy Using ¹³¹I-8H9 for Central Nervous System/Leptomeningeal Cancers
Kramer, Kim, MD

[Protocol 03-133]
A Phase I Study of Oral Yeast Beta-glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients with Metastatic Neuroblastoma
Modak, Shakeel, MD

[Protocol 05-073]
A Phase I Study of an Ethanol-Lock Strategy to Prevent Central Venous Catheter Infections Among Patients with High-Risk Neuroblastoma
Kayton, Mark, MD

[Protocol 07-047]
A Phase I/II Study of Temsirolimus (CCI-779) in Children with Relapsed or Refractory Solid Tumors (Part 2)
Dunkel, Ira, MD

[Protocol 07-060]
A Phase II Study of Anti-GD2 Antibody 3F8 and GM-CSF for High-Risk Neuroblastoma
Kushner, Brian, MD

[Protocol 03-077]
A Phase II Study of Intrathecal I¹³¹-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Kramer, Kim, MD

[Protocol 05-122]
A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
Trippett, Tanya, MD

[Protocol 07-179]
A Pilot Phase II Study of Targeted Radiotherapy with ¹³¹I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
Modak, Shakeel, MD

[Protocol 04-148]
Combination of Targeted I¹³¹-3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients with Relapsed or Refractory Neuroblastoma: A Phase I Study
Modak, Shakeel, MD

[Protocol 06-072]
Molecular Characterization of Neuroblastic Tumors and Clinical Outcome
Cheung, Nai-Kong, MD, PhD

[Protocol 00-109]

Last Updated: Jan. 25, 2006

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org